2nd EurocanPlatform translational research course is good for networking

Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal
2nd EurocanPlatform translational research course is good for networking ( Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal )
6 Jan 2015

Reasons to attend the EurocanPlatform translational research course 2015

Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany
Reasons to attend the EurocanPlatform translational research course 2015 ( Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany )
6 Jan 2015

Immunotherapy of cancer: recent progress and future challenges

Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden
Immunotherapy of cancer: recent progress and future challenges ( Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015

Epigenome deregulation in cancer

Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France
Epigenome deregulation in cancer ( Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France )
6 Jan 2015

Aims and successes of the 2nd EurocanPlatform project translational research course

Christina von Gertten, Karolinska Institutet, Stockholm, Sweden
Aims and successes of the 2nd EurocanPlatform project translational research course ( Christina von Gertten, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015

New approaches and new partnership models for biomarker based clinical research

Dr Denis Lacombe, EORTC, Brussels, Belgium
New approaches and new partnership models for biomarker based clinical research ( Dr Denis Lacombe, EORTC, Brussels, Belgium )
6 Jan 2015

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Prof Franco Cavalli, Prof Gordon McVie
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )
1 Jun 2014

Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;
Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General  Hospital, Southampton, UK; )
9 May 2014

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA
New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute  of Emory University, Atlanta, USA )
8 May 2014

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC
Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )
1 May 2014

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases

Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )
1 Feb 2014